Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Bernadette Connaughton: 28,660,181 votes
Votes for Elliott Levy, M.D.: 37,095,058 votes
Say-on-pay votes for: 32,914,258 votes
+3 more
6 metrics
Votes for Bernadette Connaughton
28,660,181 votes
Election as Class I director at 2026 annual meeting
Votes for Elliott Levy, M.D.
37,095,058 votes
Election as Class I director at 2026 annual meeting
Say-on-pay votes for
32,914,258 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
6,322,885 votes
Advisory vote on executive compensation
Auditor ratification votes for
64,686,839 votes
Ratification of PricewaterhouseCoopers LLP for fiscal year ending December 31, 2026
Auditor ratification votes against
774,471 votes
Ratification of PricewaterhouseCoopers LLP
Key Terms
Annual Meeting of Stockholders, Class I directors, non-binding, advisory vote, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders regulatory
"held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”)."
Class I directors regulatory
"elected Bernadette Connaughton and Elliott Levy, M.D., to serve as Class I directors"
Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.
non-binding, advisory vote regulatory
"approved, on an advisory basis, the compensation paid to its named executive officers."
independent registered public accounting firm regulatory
"ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Broker Non-Votes financial
"The results of the stockholders’ vote with respect to the election of such Class I directors were as follows"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
What did Editas Medicine (EDIT) stockholders decide at the 2026 annual meeting?
Stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for 2026. These routine governance decisions confirm board composition, support the pay program, and maintain continuity with the current independent audit firm.
Who was elected to the Editas Medicine (EDIT) board in 2026 and for how long?
Bernadette Connaughton and Elliott Levy, M.D., were elected as Class I directors to serve until the 2029 annual meeting. Their terms continue until that meeting and until their successors are duly elected and qualified, maintaining board oversight and continuity for the company.
How did Editas Medicine (EDIT) stockholders vote on executive compensation in 2026?
Stockholders approved the non-binding advisory vote on named executive officer compensation with 32,914,258 votes for, 6,322,885 against, and 212,587 abstaining. There were 26,404,190 broker non-votes. This indicates overall stockholder support for the company’s existing executive pay structure.
Which audit firm did Editas Medicine (EDIT) stockholders ratify for fiscal year 2026?
Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 64,686,839 votes for, 774,471 against, and 392,610 abstentions, confirming continued engagement of the same external auditor.
What were the vote totals for Editas Medicine (EDIT) director Elliott Levy, M.D.?
Elliott Levy, M.D., received 37,095,058 votes for and 2,354,672 votes withheld, along with 26,404,190 broker non-votes. These results confirm his election as a Class I director, with a term running until the 2029 annual meeting of stockholders.